Published • loading... • Updated
Novo Has a Problem with Ozempic’s ‘Day After’: CagriSema, Oral Wegovy and Five New Blockbusters to Survive Semaglutide
Summary by Merca2.es
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Novo has a problem of the future: he must build a business capable of surviving semaglutide. However, he has not yet managed to convince the market that his new engines will be enough. That is the main conclusion that is drawn from his Capital Markets Day held on Monday in London, according to the opinions of Emmanuel Papadakis [...] The Novo entry has a problem with the ‘day after’ of Ozempic: CagriSema, Wegovy oral and five new ‘blockbusters’ …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
